semaglutide nash results for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers Metabolic dysfunction-associated steatotic liver disease

Appetite Control GLP-1 helps decrease your hunger and stops you from overeating by making you feel full

Why 2019-2026 Changed the Pipeline The 2019-2026 period began with a major milestone: oral semaglutide was approved for type 2 diabetes in 2019, proving that peptide therapeutics could move beyond injections when absorption technology worked

JAMA Health Forum

Program execution and performance Lead day-to-day execution of GLP-1 program initiatives, converting strategy and ideas into clear project plans, timelines, and ownership

Jenny built Phoenix NP after hearing, over and over, from women whose concerns about GLP-1 medications were dismissed by other providers